The EMA has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one – Sanofi
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged… read more.